Compare Stocks: IPHA, ACRS, OLMA, and PHAR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$4.27 -2.7%	$5.70	$1.74 ▼ $6.60	$613.83M	0.87	3.11 million shs	7.02 million shs
IPHA Innate Pharma	$1.58 +1.3%	$1.96	$1.17 ▼ $2.71	$176.52M	0.72	55,349 shs	106,871 shs
OLMA Olema Pharmaceuticals	$8.25 +0.2%	$10.37	$6.65 ▼ $36.26	$719.67M	2	1.27 million shs	1.01 million shs
PHAR Pharming Group	$9.80 +0.5%	$11.09	$9.62 ▼ $21.34	$690.09M	-0.05	36,577 shs	10,813 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-2.73%	-21.36%	-30.79%	-24.02%	+129.57%
IPHA Innate Pharma	+1.28%	-7.06%	-24.04%	-14.13%	-23.30%
OLMA Olema Pharmaceuticals	+0.24%	-4.18%	-23.26%	-34.68%	-25.68%
PHAR Pharming Group	+0.51%	-6.84%	-12.73%	-31.97%	-39.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$4.27 -2.7%	$5.70	$1.74 ▼ $6.60	$613.83M	0.87	3.11 million shs	7.02 million shs
IPHA Innate Pharma	$1.58 +1.3%	$1.96	$1.17 ▼ $2.71	$176.52M	0.72	55,349 shs	106,871 shs
OLMA Olema Pharmaceuticals	$8.25 +0.2%	$10.37	$6.65 ▼ $36.26	$719.67M	2	1.27 million shs	1.01 million shs
PHAR Pharming Group	$9.80 +0.5%	$11.09	$9.62 ▼ $21.34	$690.09M	-0.05	36,577 shs	10,813 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-2.73%	-21.36%	-30.79%	-24.02%	+129.57%
IPHA Innate Pharma	+1.28%	-7.06%	-24.04%	-14.13%	-23.30%
OLMA Olema Pharmaceuticals	+0.24%	-4.18%	-23.26%	-34.68%	-25.68%
PHAR Pharming Group	+0.51%	-6.84%	-12.73%	-31.97%	-39.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	165.42% Upside
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	321.94% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	392.12% Upside
PHAR Pharming Group	2.20	Hold	$38.67	294.56% Upside

Current Analyst Ratings Breakdown

Latest IPHA, ACRS, OLMA, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$38.00
9/22/2026	IPHA Innate Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/21/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/17/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$8.22M	72.64	N/A	N/A	$0.85 per share	5.02
IPHA Innate Pharma	$4.23M	41.72	N/A	N/A	($0.26) per share	-6.08
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
PHAR Pharming Group	$376.13M	1.84	$0.20 per share	48.62	$3.95 per share	2.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	81.67	36.30	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)

Latest IPHA, ACRS, OLMA, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
IPHA Innate Pharma	N/A	0.60	N/A
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
IPHA Innate Pharma	0.16%
OLMA Olema Pharmaceuticals	91.78%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
IPHA Innate Pharma	31.89%
OLMA Olema Pharmaceuticals	12.56%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	73	139.82 million	133.11 million	Optionable
IPHA Innate Pharma	163	111.72 million	76.09 million	Not Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable

IPHA, ACRS, OLMA, and PHAR Headlines

Recent News About These Companies

HC Wainwright Raises Earnings Estimates for Pharming Group

October 2, 2026 | marketbeat.com

Grifols (NASDAQ:GRFS) & Pharming Group (NASDAQ:PHAR) Head to Head Contrast

October 2, 2026 | americanbankingnews.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Rating of "Hold" from Brokerages

October 2, 2026 | americanbankingnews.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Rated "Hold" by Wall Street Analysts

October 2, 2026 | marketbeat.com

Q3 EPS Estimates for Pharming Group Boosted by HC Wainwright

October 1, 2026 | americanbankingnews.com

Analysts Issue Forecasts for Pharming Group Q3 Earnings

October 1, 2026 | marketbeat.com

Pharming: Chief Executive Officer Fabrice Chouraqui Steps Down with Immediate Effect

September 30, 2026 | ideal-investisseur.frI

Pharming Appoints Leverne Marsh, Kenneth Lynard as Co-CEOs

September 29, 2026 | finance.yahoo.com

Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

September 29, 2026 | pharmexec.comP

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened

September 29, 2026 | marketbeat.com

Pharming Group N.V.: Pharming announces CEO transition

September 29, 2026 | finanznachrichten.de

Pharming CEO Fabrice Chouraqui Steps Down, Names Leverne Marsh, Kenneth Lynard Interim Co-CEOs

September 29, 2026 | rttnews.com

Pharming CEO Fabrice Chouraqui Resigns After Disagreement on Direction

September 29, 2026 | marketwatch.com

Pharming announces CEO transition

September 29, 2026 | globenewswire.com

FDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS

September 26, 2026 | rttnews.com

Pharming Group N.V. Announces U.S. FDA Acceptance And Priority Review Of sNDA For Lower Doses Of Joenja To Treat Children With APDS

September 25, 2026 | marketscreener.comM

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Time to Buy?

September 25, 2026 | marketbeat.com

Pharming Says FDA Accepts sNDA for Lower-Dose Joenja in Children With APDS

September 25, 2026 | marketscreener.comM

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

September 25, 2026 | globenewswire.com

Pharming Group's (PHAR) Buy Rating Reaffirmed at HC Wainwright

September 22, 2026 | marketbeat.com

Pharming Group N.V. Announces Positive Phase II Topline Data For Leniolisib In PIDs With Immune Dysregulation Accepted As Late-Breaking Abstract At ESID 2026

September 22, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ACRS, OLMA, and PHAR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$4.27 -0.12 (-2.73%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$4.36 +0.09 (+2.08%)

As of 07:32 AM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Innate Pharma NASDAQ:IPHA

$1.58 +0.02 (+1.28%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.32%)

As of 07:57 AM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Olema Pharmaceuticals NASDAQ:OLMA

$8.25 +0.02 (+0.24%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$8.22 -0.03 (-0.30%)

As of 08:06 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Pharming Group NASDAQ:PHAR

$9.80 +0.05 (+0.51%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$9.81 +0.01 (+0.11%)

As of 04:42 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, ACRS, OLMA, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, ACRS, OLMA, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, ACRS, OLMA, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ACRS, OLMA, and PHAR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Innate Pharma NASDAQ:IPHA

Olema Pharmaceuticals NASDAQ:OLMA

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, ACRS, OLMA, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, ACRS, OLMA, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, ACRS, OLMA, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ACRS, OLMA, and PHAR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Innate Pharma NASDAQ:IPHA

Olema Pharmaceuticals NASDAQ:OLMA

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools